Uncommon Presentation and Therapeutic Strategies in Pediatric Relapsed/Refractory ALK-Positive ALCL.
AI interpretation is pending for this paper.
Open original publication →What the AI sees
Not AI summarized yet.
Research significance
Pending deeper interpretation.
Source abstract
BACKGROUND: Anaplastic large cell lymphoma (ALCL) is an aggressive T-cell lymphoma that, rarely, can present with secondary haemophagocytic lymphohistiocytosis (HLH). OBSERVATIONS: A 6-year-old boy with ALK-positive ALCL and HLH required intensive care and chemotherapy, experienced multiple relapses, and ultimately achieved remission with crizotinib, ruxolitinib, dexamethasone, and allogeneic stem cell transplant. CONCLUSIONS: This case illustrates the clinical challenges of treating ALK-positive ALCL with concurrent HLH and highlights the role of targeted therapies. As molecular understanding of ALCL increases, integrating novel targeted agents may improve outcomes, particularly in relapsed or high-risk disease.